Changing the future of Oncology.
About Sutro Biopharma
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Platform
Precision protein engineering generates superior molecules
Products
3 product candidates in the clinic as a result of research innovations
Partners
Premier collaborations with Bristol Myers Squibb, Merck, EMD Serono and Vaxcyte (formerly known as SutroVax)
People
Great people making excellence happen, every day!
Technology
Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.
Pipeline
Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and cytokine derivatives targeting immuno-oncology pathways.
Partnerships
Recent News
SutroVax Announces Name Change to Vaxcyte
Foster City, Calif., May 21, 2020 – SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Company’s mission to improve global health by developing superior and novel...
Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
SOUTH SAN FRANCISCO, Calif., May 21, 2020– Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focusedon the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards – Carlos Paya, MD, PhD, and Lainie Martin, MD
SOUTH SAN FRANCISCO, Calif., May 21, 2020– Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focusedon the application of precise protein engineering and rational design to create next-generation oncology...
Careers
At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference both as individuals and as part of a team.
